Author:
Dhawan Vijay,Niethammer Martin H,Lesser Martin L,Pappas Karalyn N,Hellman Matthew,Fitzpatrick Toni M,Bjelke David,Singh Jaskirat,Quatarolo Loreta M,Choi Yoon Young,Oh Alice,Eidelberg David,Chaly Thomas
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging
Reference22 articles.
1. Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol. 2004;61:1224–9.
2. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol. 2011;10:309–19.
3. Chevalme YM, Montravers F, Vuillez JP, Zanca M, Fallais C, Oustrin J, et al. FDOPA-(18F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union. Braz Arch Biol Tech. 2007;50:77–90.
4. Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2009;36:454–62.
5. Calabria FF, Calabria E, Gangemi V, Cascini GL. Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders. Hell J Nucl Med. 19:33–41.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献